Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine.
Quiambao B, Peyrani P, Li P, Cutler MW, Van Der Wielen M, Perez JL, Webber C. Quiambao B, et al. Among authors: peyrani p. Hum Vaccin Immunother. 2020 Jun 2;16(6):1272-1279. doi: 10.1080/21645515.2020.1744363. Epub 2020 May 13. Hum Vaccin Immunother. 2020. PMID: 32401600 Free PMC article. Clinical Trial.
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.
Borja-Tabora CFC, Peyrani P, Webber C, Van der Wielen M, Cheuvart B, De Schrevel N, Bianco V, Aris E, Cutler M, Li P, Perez JL. Borja-Tabora CFC, et al. Among authors: peyrani p. BMC Infect Dis. 2020 Jun 18;20(1):426. doi: 10.1186/s12879-020-05104-5. BMC Infect Dis. 2020. PMID: 32552685 Free PMC article. Clinical Trial.
A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age.
Klein NP, Peyrani P, Yacisin K, Caldwell N, Xu X, Scully IL, Scott DA, Jansen KU, Gruber WC, Watson W. Klein NP, et al. Among authors: peyrani p. Vaccine. 2021 Sep 7;39(38):5428-5435. doi: 10.1016/j.vaccine.2021.07.004. Epub 2021 Jul 24. Vaccine. 2021. PMID: 34315611 Free article. Clinical Trial.
Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia.
Isturiz RE, Ramirez J, Self WH, Grijalva CG, Counselman FL, Volturo G, Ostrosky-Zeichner L, Peyrani P, Wunderink RG, Sherwin R, Overcash JS, Oliva SP, File T, Wiemken TL, McLaughlin JM, Pride MW, Gray S, Alexander R, Ford KD, Jiang Q, Jodar L. Isturiz RE, et al. Among authors: peyrani p. Vaccine. 2019 May 31;37(25):3352-3361. doi: 10.1016/j.vaccine.2019.04.087. Epub 2019 May 6. Vaccine. 2019. PMID: 31072732 Free article.
The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study.
Wiemken TL, Carrico RM, Klein SL, Jonsson CB, Peyrani P, Kelley RR, Aliberti S, Blasi F, Fernandez-Gonzalez R, Lopardo G, Ramirez JA; CAPO Investigators. Wiemken TL, et al. Among authors: peyrani p. Vaccine. 2014 Apr 17;32(19):2198-203. doi: 10.1016/j.vaccine.2014.02.048. Epub 2014 Mar 6. Vaccine. 2014. PMID: 24613522
Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults.
Isturiz R, Grant L, Gray S, Alexander-Parrish R, Jiang Q, Jodar L, Peyrani P, Ford KD, Pride MW, Self WH, Counselman F, Volturo G, Ostrosky-Zeichner L, Wunderink RG, Sherwin R, Overcash JS, File T, Ramirez J. Isturiz R, et al. Among authors: peyrani p. Clin Infect Dis. 2021 Oct 5;73(7):1216-1222. doi: 10.1093/cid/ciab375. Clin Infect Dis. 2021. PMID: 33982098 Free PMC article.
107 results